01:04 , Jun 28, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb joins Pfizer board; plus Adaptimmune, Xencor, Arcus and more

Pfizer Inc. (NYSE:PFE) appointed former FDA Commissioner Scott Gottlieb to its board. Gottlieb is joining the board's regulatory and compliance and science and technology committees. Since leaving the FDA in early April, Gottlieb returned to...
20:45 , Jun 6, 2019 |  BC Extra  |  Financial News

How Third Rock will deploy $770M in its biggest fund yet

Staff changes and recent trends in private capital dynamics aren’t likely to sway Third Rock Ventures’ strategy as it invests its new $770 million Fund V, the firm’s largest-ever vehicle. The firm will, however, have...
23:04 , Dec 20, 2018 |  BC Innovations  |  Finance

Third Rock keeps its options open

Third Rock Ventures is cementing its strategy to create newcos that can succeed as stand-alone companies. The VC has ditched the build-to-buy model in favor of one that gives a pharma broad options to multiple...
22:24 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc....
23:08 , Aug 10, 2018 |  BioCentury  |  Finance

Takeda gets Ambys-tious

After a two-year search, Takeda Pharmaceutical Co. Ltd.’s equity investment and option deal with newco Ambys Medicines finally gets the ball rolling on the pharma’s goal of building a liver franchise within its core area...
11:02 , Aug 8, 2018 |  BC Extra  |  Financial News

Ambys launches with $140M from series A, Takeda deal

Liver disease company Ambys Medicines (Redwood City, Calif.) launched on Wednesday with $140 million in funding from a series A round and an option partnership with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Ambys' $60 million series...